DXCM

Dexcom Inc

Add to Watchlist

Advanced Chart

89.350

-0.18(-0.201%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

89.960

Open

89.640

VWAP

Vol

2.47M

Mkt Cap

35.03B

Low

88.970

Amount

EV/EBITDA(TTM)

38.30

Total Shares

397.68M

34.90B

EV/OCF(TTM)

36.20

P/S(TTM)

8.86

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

1.28B

+14.88%

0.696

+54.7%

1.17B

+17.63%

0.567

+26.07%

1.12B

+11.98%

0.445

+3.52%

Estimates Revision

The market is revising Upward the revenue expectations for DexCom, Inc. (DXCM) for FY2025, with the revenue forecasts being adjusted by 0.13% over the past three months. During the same period, the stock price has changed by 25.32%.

Revenue Estimates for FY2025

Revise Upward

+0.13%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.37%

In Past 3 Month

Stock Price

Go Up

+25.32%

In Past 3 Month

20 Analyst Rating

11.32% Upside

Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 99.46 USD with a low forecast of 86.67 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

18 Buy

2 Hold

0 Sell

Strong Buy

11.32% Upside

Current: 89.350

Low

86.67

Averages

99.46

High

110.00

11.32% Upside

Current: 89.350

Low

86.67

Averages

99.46

High

110.00

Mizuho

Anthony Petrone

Outperform

maintain

$95 -> $100

2025-07-16

Reason

Mizuho

Anthony Petrone

Price Target

$95 -> $100

2025-07-16

maintain

Outperform

Reason

Mizuho analyst Anthony Petrone raised the firm's price target on DexCom to $100 from $95 and keeps an Outperform rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.

Morgan Stanley

Patrick Wood

Equal Weight

maintain

$82 -> $89

2025-07-15

Reason

Morgan Stanley

Patrick Wood

Price Target

$82 -> $89

2025-07-15

maintain

Equal Weight

Reason

Morgan Stanley analyst Patrick Wood raised the firm's price target on DexCom to $89 from $82 and keeps an Equal Weight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.

Truist

initiated

$102

2025-06-17

Reason

Truist

Price Target

$102

2025-06-17

initiated

Reason

Goldman Sachs

Buy

initiated

$104

2025-05-29

Reason

Goldman Sachs

Price Target

$104

2025-05-29

initiated

Buy

Reason

Goldman Sachs initiated coverage of DexCom with a Buy rating and $104 price target as part of a broader research note launching coverage on Diabetes Medical Technology. Diabetes technology is poised to sustain double-digit growth, and DexCom offers potential upside from consumer-related adoption and strong profitability leverage that should evidence through the balance of 2025, the analyst tells investors in a research note. The market also underappreciates the degree of P&L upside in DexCom model as gross margins scale, Goldman Sachs added.

Citi

NULL -> Buy

maintain

$82 -> $102

2025-05-22

Reason

Citi

Price Target

$82 -> $102

2025-05-22

maintain

NULL -> Buy

Reason

Citi raised the firm's price target on DexCom to $102 from $82 and keeps a Buy rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.

Mizuho

Anthony Petrone

Buy

Initiates

$85

2025-04-10

Reason

Mizuho

Anthony Petrone

Price Target

$85

2025-04-10

Initiates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Dexcom Inc (DXCM.O) is 40.91, compared to its 5-year average forward P/E of 98.09. For a more detailed relative valuation and DCF analysis to assess Dexcom Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

98.09

Current PE

40.91

Overvalued PE

143.87

Undervalued PE

52.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

52.16

Current EV/EBITDA

23.39

Overvalued EV/EBITDA

78.26

Undervalued EV/EBITDA

26.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

12.33

Current PS

7.31

Overvalued PS

16.36

Undervalued PS

8.30

Financials

Annual

Quarterly

FY2025Q1

YoY :

+12.49%

1.04B

Total Revenue

FY2025Q1

YoY :

+32.25%

133.70M

Operating Profit

FY2025Q1

YoY :

-28.01%

105.40M

Net Income after Tax

FY2025Q1

YoY :

-25.71%

0.26

EPS - Diluted

FY2025Q1

YoY :

-36.44%

96.80M

Free Cash Flow

FY2025Q1

YoY :

-6.82%

56.85

Gross Profit Margin - %

FY2025Q1

YoY :

-36.04%

10.17

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

2.7M

USD

3-6

Months

6.4M

USD

6-9

Months

3.8M

USD

0-12

Months

250.7K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

16.2K

Volume

6-9

Months

147.1K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

930.4K

Volume

Months

6-9

2.0M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

172.5K

USD

3-6

Months

81.0K

USD

6-9

Months

150.0K

USD

0-12

Months

0.0

USD

Bought

0-3

97.0K

USD

Months

3-6

107.5K

USD

Months

6-9

8.0K

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

2.7M

USD

3-6

Months

6.4M

USD

6-9

Months

3.8M

USD

0-12

Months

250.7K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

DXCM News & Events

Events Timeline

2025-07-01 (ET)

2025-07-01

10:17:40

Wells says CBP proposal for CGMs expected, insulin pumps inclusion 'a surprise'

2025-07-01

08:52:27

Diabetes device maker shares slide after payment scheduling proposal

2025-06-24 (ET)

2025-06-24

12:14:59

Diabetes stocks rally after RFK comments on HHS campaign

News

3.0

03:00 AMNASDAQ.COM

DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

5.0

07-28Newsfilter

Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio

6.5

07-21NASDAQ.COM

AVLV's Underlying Holdings Imply 10% Gain Potential

People Also Watch

TPL

Texas Pacific Land Corp

Rockwell Automation Inc

353.900

USD

-0.60%

Dupont De Nemours Inc

Take-Two Interactive Software Inc

Hartford Insurance Group Inc

Willis Towers Watson PLC

FAQ

What is Dexcom Inc (DXCM) stock price today?

The current price of DXCM is 89.35 USD — it has decreased -0.2 % in the last trading day.

DXCM

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

DXCM News & Events

Events Timeline

News

People Also Watch

FAQ

What is Dexcom Inc (DXCM) stock price today?

What is Dexcom Inc (DXCM)'s business?

What is the price predicton of DXCM Stock?

What is Dexcom Inc (DXCM)'s revenue for the last quarter?

What is Dexcom Inc (DXCM)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Dexcom Inc (DXCM)'s fundamentals?

How many employees does Dexcom Inc (DXCM). have?

What is Dexcom Inc (DXCM) market cap?